Emergex Vaccines is closing in on the delivery of clinical data on its dengue vaccine. With the clinical trial holding its last participant last visit in March, the British biotech expects to report data over the summer.
The study represents a test of Emergex’s synthetic T-cell adaptive vaccine platform. Using the platform, Emergex is seeking to program immune cells to destroy pathogen-producing cells. The platform brings together a library of pathogen-derived peptides that are presented to CD8+ T cells and a nanoparticle carrier system for delivering synthetic peptides via microneedles.
